The My MD3 genetic analysis software program was created for analyzing genetic diseases and for analyzing genome wide association studies. The main goal of My MD3 is to provide superior software solutions to geneticists in order to accelerate research efforts in this area. It was co-founded by Dr. David Page, who is a world renowned geneticist and was one of the co-discoverers of the Human Genome Project (HGP). His research focuses on developing new tools that will assist geneticists in the future in their research efforts. The software has been downloaded over fifteen million times, making it one of the most popular pieces of software available today.
Because of its similarity to the human genome, the MMD3 gene may also be involved in another common pathway that links muscle dystrophy, which is a muscle disease, and diabetes. Because the software is designed to examine genetic patterns, the association of muscular dystrophy with MMD3 may be detected earlier in diagnosis, reducing the need for surgical treatment or life-saving dialysis. Because this is an important area of study in genetic disorders, the development of new technologies and diagnostic testing will greatly improve the accuracy of future treatments and possible cures. Because of these exciting developments, many people have learned about My MD3 and its ability to generate a computer-generated image of a person's DNA. Because the analysis is based on the genetic blueprint of humans, testing for diseases or traits within a person's DNA at this level is very accurate and useful.
My MD3 can also help in the diagnosis of conditions such as: Dupuytren's Contracture, Legg-Calve-Perthes Disease, Duchenne's Cystitis, Knee Levethralgia, and Paget's Sign. This software can also be used for gene mapping and other genome wide studies of complex biological mechanisms. In addition, studies of myopathies, specifically diseases of the musculoskeletal system, are currently underway using MMD3. Some diseases, such as spinal muscular atrophy, involve multiple regions of the nervous system, making it difficult for specialists to evaluate the consequences of dysfunctions of multiple genes. Other diseases affect only one region of the body, making it more difficult to assess the impact of myopathies, especially in terms of treatment efficacy.
